Berlin - Delayed Quote EUR
BioNTech SE (22UA.BE)
92.80
+1.80
+(1.98%)
At close: May 2 at 3:28:02 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,751,100
2,751,100
3,819,000
17,310,600
18,976,700
Cost of Revenue
541,300
541,300
599,800
2,995,000
2,911,500
Gross Profit
2,209,800
2,209,800
3,219,200
14,315,600
16,065,200
Operating Expense
2,805,500
2,805,500
2,315,000
2,011,800
1,138,100
Operating Income
-595,700
-595,700
904,200
12,303,800
14,927,100
Net Non Operating Interest Income Expense
425,000
425,000
349,700
29,600
-25,800
Other Income Expense
-507,000
-507,000
-67,800
620,700
145,100
Pretax Income
-677,700
-677,700
1,186,100
12,954,100
15,046,400
Tax Provision
-12,400
-12,400
255,800
3,519,700
4,753,900
Net Income Common Stockholders
-665,300
-665,300
930,300
9,434,400
10,292,500
Diluted NI Available to Com Stockholders
-665,300
-665,300
930,300
9,434,400
10,292,500
Basic EPS
-2.77
--
3.87
38.78
42.18
Diluted EPS
-2.77
--
3.83
37.77
39.63
Basic Average Shares
240,400
--
240,600
243,300
244,000
Diluted Average Shares
240,400
--
242,700
249,800
259,700
Total Operating Income as Reported
-1,314,300
-1,314,300
690,400
12,642,700
15,283,800
Total Expenses
3,346,800
3,346,800
2,914,800
5,006,800
4,049,600
Net Income from Continuing & Discontinued Operation
-665,300
-665,300
930,300
9,434,400
10,292,500
Normalized Income
-167,426
-167,426
983,455.20
8,982,530.40
10,193,251.60
Interest Income
437,600
437,600
357,600
48,500
1,500
Interest Expense
12,600
12,600
7,900
18,900
5,400
Net Interest Income
425,000
425,000
349,700
29,600
-25,800
EBIT
-665,100
-665,100
1,194,000
12,973,000
14,927,100
EBITDA
-367,100
-367,100
1,377,400
13,096,300
15,002,300
Reconciled Cost of Revenue
541,300
541,300
599,800
2,995,000
2,911,500
Reconciled Depreciation
298,000
298,000
183,400
123,300
75,200
Net Income from Continuing Operation Net Minority Interest
-665,300
-665,300
930,300
9,434,400
10,292,500
Total Unusual Items Excluding Goodwill
-507,000
-507,000
-67,800
620,700
145,100
Total Unusual Items
-507,000
-507,000
-67,800
620,700
145,100
Normalized EBITDA
139,900
139,900
1,445,200
12,475,600
14,857,200
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-9,126
-9,126
-14,644.80
168,830.40
45,851.60
12/31/2021 - 10/15/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HTD.SG Corcept Therapeutics Inc
64.08
+1.65%
0OT.DU Ocular Therapeutix Inc
7.67
+4.78%
VX1.HA Vertex Pharmaceuticals Inc
439.60
-0.92%
VX1.DU Vertex Pharmaceuticals Inc
440.35
-0.94%
VX1.MU Vertex Pharmaceuticals Inc
439.25
-0.82%
1T3.BE Syndax Pharmaceuticals Inc
12.00
-4.00%
VX1.BE Vertex Pharmaceuticals Inc
444.00
+0.90%
VRTX.VI Vertex Pharmaceuticals Incorporated
440.30
-1.21%
VX1.HM Vertex Pharmaceuticals Inc
439.65
-0.91%
ALZCUR.ST AlzeCure Pharma AB (publ)
2.4500
+3.38%